Glaxosmithkline Pharmaceuticals Limited · NSE:GLAXO
Glaxosmithkline Pharmaceuticals — Q2 FY25 Earnings Presentation
10 slides from Glaxosmithkline Pharmaceuticals's earnings presentation, Oct 29, 2024
Slide 1: Outcome of Schedule of Analyst / Institutional Investor Meetings
GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400 030 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494 Web: www.gsk-india.com Email: askus@gsk.com 29th October 2024 To, BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Phiroze Jeejeebhoy Towers Exc
Slide 2: GlaxoSmithKline Pharmaceuticals Limited
Slide 3: Bhushan Akshikar, Managing Director and Juby Chandy, Chief Financial Officer
Bhushan Akshikar, Managing Director Mr. Bhushan Akshikar has an experience of over 14 years in key leadership roles in GSK across India, Middle East, Russia CIS & Africa region. Before joining GSK, Bhushan spent 15 years with Johnson & Johnson, in local and regional positions in India, S. Korea and
Slide 4: General Medicines and Pediatric Vaccines commercial highlights
General Medicines: Majority key brands Improving our SoV and Elevating customer growing at par with market experience through digital innovation 400K+ Unique HCPs reached (F2F + Digital) ~9.2Mn Digital touchpoints Pediatric Vaccines continues to lead the overall Vx market +26% HCP touchpoints 29 Oct
Slide 5: Strategic Resourcing and One GSK Approach
STORY OF UNITING SCIENCE, ENHANCED ACCESS AND LEADERSHIP 2000+ Severe asthma patients STRATEGIC RESOURCING AND ONE GSK APPROACH benefitted #1 Accelerate Initiation of Nucala #2 Elevate long-term Tx goals for SA patients 5.4% EI> 100 MS (Sept) in M-o-M in 2024 SITT class #1 Early optimization
Slide 6: Shingles vaccination awareness campaign
SK Agar aapko Inactive Diabetes Chickenpox virus can lead to Shingles years later. Yeh Sci Hi VACCINATION CAN HELP Jy VACCINATION CAN HELP PREVENT SHINGLES" POR PREVENT SHINGLES SF In core 50+ patient cohort. All-new campaign In core 50+ patient Consumers initiating Content Integration Anupama, feat
Slide 7: Jul-Sep'24 (Q2 FY25): Financial Highlights
Jul-Sep’24 (Q2 FY25): Financial Highlights Revenue EBITDA PAT ₹1000cr ₹319cr ₹249cr Growth +5% Growth +11% Growth+15% Margin: 32% Margin: 25% First-ever revenue of ₹1000 cr EBITDA margin +180 bps (YoY) PAT +230 bps (YoY) ▪ General Medicines key brands holding on their market share despite headwinds,
Slide 8: Apr-Sep'24 (H1 FY25): Financial Highlights
Apr-Sep’24 (H1 FY25): Financial Highlights Revenue EBITDA PAT ₹1811cr ₹548cr ₹430cr Growth +7% Growth +28% Growth+24% Margin: 30.3% Margin: 24% Revenue growth +7% EBITDA margin +500 bps (YoY) PAT +340 bps (YoY) ▪ General Medicine key Pharma brands volume ▪ PAT stepped up due to stable gross growth +
Slide 9: Century of Trust
Century of Trust Strategic programmes for building GSK’s reputation 8
Slide 10: gsk.com
gsk.com
GlaxoSmithKline Pharmaceuticals — Q2 FY25 Earnings Presentation on 6ix